Article Text

Download PDFPDF
A 15-year population-based cohort study of the incidence of Parkinson's disease and dementia with Lewy bodies in an elderly French cohort
  1. F Perez1,
  2. C Helmer2,
  3. J F Dartigues1,2,
  4. S Auriacombe3,
  5. F Tison1
  1. 1Parkinson's Disease and Related Disorders Unit, Department of Clinical Neurosciences, University Hospital, Bordeaux, France
  2. 2INSERM U 897, Public Health and Development Institute (ISPED), Bordeaux University, Bordeaux, France
  3. 3Memory Disorders and Alzheimer's Disease Clinic (CMRR), Department of Clinical Neurosciences, University Hospital, Bordeaux, France
  1. Correspondence to Professor François Tison, Service de Neurologie, Hôpital Haut-Lévèque, USN, CHU de Bordeaux, Av de Magellan, 33604 Pessac Cedex, France; francois.tison{at}


Objective To provide global and age-related incidence over 65 years of Parkinsonian syndromes (PS), Parkinson's disease (PD) and suspected dementia with Lewy bodies (DLB).

Methods A 15-year prospective population-based elderly cohort study in South-Western France (PAQUID).

Results Incidences found were: 557.7/100 000 person-years for PS, 263 per 100 000 person-years for PD and 112 per 100 000 person-years for suspected DLB. The incidence of all PS, PD and suspected DLB was greater in men. The age-specific incidence of PD decreased over 85, while that of DLB continuously increased, even in the oldest individuals.

Conclusions The authors provide new data on PD and suspected DLB incidence in a large population-based French cohort of subjects aged over 65 and followed up for 15 years. PD incidence decreased in the oldest old contrary to that of suspected DLB cases and Alzheimer's disease.

  • Incidence
  • cohort
  • Parkinson's disease
  • dementia with Lewy bodies
  • age
  • epidemiology
  • Lewy body

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests Novartis Pharma France, IPSEN France.

  • Patient consent Obtained.

  • Ethics approval Ethics approval was provided by the Bordeaux 2 University Ethics Committee in 1988.

  • Provenance and peer review Not commissioned; externally peer reviewed.